fluidenews.com

Legend Biotech experienced an exceptional first quarter in 2026, marked by a substantial increase in CARVYKTI sales and notable progress in its developmental pipeline. The company’s flagship CAR T therapy, CARVYKTI, demonstrated remarkable growth, fueled by its expanded use in earlier treatment stages within the United States and significant international market penetration.

This quarter’s financial performance underscores Legend Biotech’s strategic success and operational efficiency. Despite a temporary dip in gross margins due to one-time ramp-up costs at newly expanded manufacturing facilities, the company remains confident in a swift recovery, projecting margins to exceed 50% in the upcoming quarter. Furthermore, Legend Biotech is making significant strides in its in vivo CAR T programs, with both BCMA and GPRC5D programs entering Phase I clinical trials. The company anticipates releasing initial data for its non-Hodgkin's lymphoma program this year and is on track to achieve overall profitability on an adjusted basis by the end of 2026.

Legend Biotech’s ongoing commitment to innovation and market expansion positions it for continued success in the competitive biopharmaceutical landscape. The positive momentum observed in CARVYKTI’s adoption, coupled with a robust and advancing pipeline, reflects the company’s dedication to addressing unmet medical needs and delivering groundbreaking therapeutic solutions. This strategic direction not only strengthens its market presence but also promises a future of sustained growth and significant contributions to patient care.